Generic Name and Formulations:
Quinine sulfate 324mg; caps.
Indications for QUALAQUIN:
Treatment of uncomplicated P. falciparum malaria (including chloroquine-resistant strains).
Take with food. ≥16yrs: 648mg every 8hrs for 7 days. Severe renal failure: 648mg once, after 12hrs start 324mg every 12hrs. Hepatic impairment (severe): not recommended; (mild and moderate): monitor closely.
<16yrs: not established.
Prolonged QT interval. G6PD deficiency. Myasthenia gravis. Mefloquine, quinidine or related allergy. History of thrombocytopenic purpura, hemolytic uremic syndrome, thrombocytopenia, blackwater fever associated with previous quinine use. Optic neuritis.
Not for treatment of severe or complicated P. falciparum malaria. Not for prevention of malaria. Not for treatment or prevention of nocturnal leg cramps; serious and life-threatening hematologic reactions may develop. Discontinue if any signs/symptoms of hypersensitivity occurs (eg, thrombocytopenic purpura, hemolytic uremic syndrome, thrombocytopenia, blackwater fever). Underlying structural heart disease. Preexisting conduction abormalities. Cardiac arrhythmias. Atrial fibrillation or atrial flutter. MI. Hypoglycemia. Hypokalemia. Bradycardia. Severe hepatic impairment: use alternative therapy. Elderly with sick sinus syndrome. Pregnancy (Cat.C). Nursing mothers.
Avoid drugs that can prolong QT interval (eg, quinidine, procainamide, disopyramide, amiodarone, sotalol, dofetilide), other CYP3A4 substrates (eg, cisapride, terfenadine, pimozide, halofantrine, quinidine), erythromycin, troleandomycin. Avoid concomitant mefloquine, halofantrine (may cause seizures or ECG changes), rifampin, ritonavir, antacids. Potentiates warfarin, oral anticoagulants, neuromuscular blocking agents. Potentiated by urinary alkalizers. May potentiate atorvastatin (monitor). May antagonize anticonvulsants (eg, carbamazepine, phenobarbital, phenytoin), CYP2D6 substrates (eg, flecainide, metoprolol, paroxetine, dextromethorphan). Increases digoxin levels (monitor). Monitor cimetidine, ranitidine, ketoconazole, tetracycline, theophylline, aminophylline.
Quinoline (cinchona alkaloids).
Headache, vasodilation, sweating, nausea, tinnitus, hearing impairment, vertigo, dizziness, blurred vision, disturbances in color perception, cardiac rhythm or conduction, vomiting, diarrhea, abdominal pain, deafness, blindness, lupus-like syndrome, blood dyscrasias; rashes (may be serious, eg, Stevens-Johnson), cardiovascular effects (eg, chest pain, AV block, torsades de pointes), hypoglycemia (esp. in pregnancy).
Caps—30, 100, 500, 1000
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Retirement Saving Behavior Associated With Psychological Distress
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Enhanced Vaccination Effectiveness in Older Adults Linked to Positive Mood
- Subjective Cognitive Decline Linked to Alzheimer Biomarker
- Unnecessary Costs Associated With Low-Cost, Low-Value Health Services
- Is Hypertension Linked to an Increased Risk of Dementia?